Johannes Czernin, MD
Dr. Johannes Czernin and his colleagues are studying the metabolic phenotype of tumor tissue and its relationship to the genotype.
The focus of Czernin's research is to refine the clinical role of molecular PET imaging. He has adopted a translational research approach by which radioactive ligand uptake in cell cultures determines the use of specific molecular imaging probes in small animals and later on in humans.
Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007; 62(2): 199-204.
Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007; 48(2): 214-20.
Weber WA, Czernin J, Phelps ME. Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture? Clin Cancer Res. 2007; 13(11): 3105-6.
Kesner AL, Dahlbom M, Huang SC, Hsueh WA, S Pio B, Czernin J, Kreissl M, Wu HM, Silverman DH. Semiautomated analysis of small-animal PET data. J Nucl Med. 2006; 47(7): 1181-6.
Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006; 12(19): 5659-67.